Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05359952
Other study ID # 21-1066
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 9, 2022
Est. completion date August 22, 2022

Study information

Verified date February 2023
Source Fox Chase Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The central goal of this randomized, controlled pilot study is to examine the feasibility, acceptability, and preliminary effects of an educational intervention (called "Starting the Conversation"; STC) on patient communication about sexual health in gynecologic cancer and other patient health outcomes. Approximately 30 women with a diagnosis of gynecologic cancer will be randomized to either participate in either the Starting the Conversation (STC) condition, consisting of an educational video, workbook, and list of resources on sexual and menopausal health, or to a control condition offering the resource guide only. Patients will be asked to review intervention materials prior to their next clinic visit with their gynecologic cancer provider. The investigators will examine effects of the interventions on patients' beliefs about communication about sexual health and on patients' communication about sexual health during clinic visits with their providers. Secondarily, the investigators will examine effects of the interventions on sexual outcomes and other health outcomes, including psychological well-being.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date August 22, 2022
Est. primary completion date August 22, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of any stage (I-IV) gynecologic cancer (uterine, ovarian, cervical, vaginal/vulvar, fallopian tube, peritoneal) - Receiving any treatment for gynecologic cancer or have completed acute treatment < 10 years ago - Attending clinic visits in the course of follow-up care (i.e., not an initial consult visit) Exclusion Criteria: - Not able to speak English - Eastern Cooperative Oncology Group (ECOG) Performance status score > 2 - Overt cognitive dysfunction or psychiatric disturbance or severe mental illness (e.g., dementia, suicidal behavior, or psychosis), as observed or judged by the researcher or referring source.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Starting the Conversation
The Starting the Conversation intervention consists of a brief educational video and accompanying workbook with activities to help prepare patients to discuss sexual and menopausal types of health concerns effectively with gynecologic cancer providers, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback. In addition, participants receive a list of sexual and menopausal resources.
Sexual and Menopausal Health Resources Only
A list of resources on sexual/menopausal health both within and outside the institution, including websites.

Locations

Country Name City State
United States Fox Chase Cancer Center Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Fox Chase Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility - Enrollment Study enrollment, defined as the proportion of participants randomized out of the number of eligible patients approached for participants. Baseline
Primary Feasibility - Retention Proportion of enrolled participants that complete the final study survey. 2 months
Primary Feasibility - Intervention Completion Proportion of participants randomized to receive the Starting the Conversation intervention who report having engaged at least somewhat with the video and/or accompanying workbook. 2 weeks
Primary Acceptability The proportion of participants randomized to receive the Starting the Conversation intervention who endorse at least 6 of 8 core components of the Starting the Conversation Intervention (defined as satisfaction with the intervention, informativeness of the intervention, helpfulness of the intervention, relevance of the intervention, ease of participation, approval of the intervention format, likelihood of recommending the intervention to others, and perceived importance of the intervention for people with gynecologic cancer). 2 weeks
Secondary Self-Efficacy - Post-Intervention Patients' confidence that they can discuss sexual concerns with their provider and ask their provider about sexual concerns. Scale ranges from 0-10, with higher scores indicating higher self-efficacy. Means will be reported. 2 weeks
Secondary Self-Efficacy - 2-Month Follow Up Patients' confidence that they can discuss sexual concerns with their provider and ask their provider about sexual concerns. Scale ranges from 0-10, with higher scores indicating higher self-efficacy. Means will be reported. 2 months
Secondary Clinical Communication - Discussion of Sexual Health Proportion of patients who discuss sexual health concerns in a clinic visit. 2 weeks
Secondary Clinical Communication - Raising Topic of Sexual Health Proportion of patients who raise the topic of sexual health concerns in a clinic visit. 2 weeks
Secondary Clinical Communication - Asking a Question About Sexual Health Proportion of patients who ask a question about sexual health concerns in a clinic visit. 2 weeks
Secondary Sexual Function Patients' self-reported sexual function will be measured using the 19-item Female Sexual Function Index (FSFI).Total scale scores range from 2 to 36, with higher scores indicating higher functioning. Mean change scores from baseline to 2 months will be reported: positive mean change scores indicate increase in sexual functioning over time while negative mean change scores indicate decrease in sexual functioning over time. 2 months
Secondary Sexual Activity A single item asking (yes/no) whether the participant had any kind of sexual activity in the past 30 days. 2 months
Secondary Psychological Distress - Depression Patients self-reported depression, as measured through depression subscale of the Hospital Anxiety & Depression Scale (HADS). The depression subscale consists of 7 items that are scored from 0 to 3. Summed scores range from 0 to 21, with higher scores indicating higher levels of depression. Means will be reported. 2 months
Secondary Psychological Distress - Anxiety Patients self-reported anxiety, as measured through anxiety subscale of the Hospital Anxiety & Depression Scale (HADS). The anxiety subscale consists of 7 items that are scored from 0 to 3. Summed scores range from 0 to 21, with higher scores indicating higher levels of anxiety. Means will be reported. 2 months
See also
  Status Clinical Trial Phase
Completed NCT04890327 - Web-based Family History Tool N/A
Not yet recruiting NCT05467319 - Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS Phase 3
Recruiting NCT05478876 - Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract N/A
Active, not recruiting NCT04899492 - Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery N/A
Terminated NCT03658109 - Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone Early Phase 1
Recruiting NCT05296512 - Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer Phase 2
Not yet recruiting NCT06398314 - Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors N/A
Completed NCT01679483 - Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer N/A
Completed NCT01444924 - Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery Phase 2
Recruiting NCT05053230 - A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer N/A
Recruiting NCT04534075 - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial Phase 3
Active, not recruiting NCT04584957 - Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.) N/A
Completed NCT03292328 - Yoga for Symptoms of Nerve Damage Caused by Chemotherapy N/A
Completed NCT02459301 - A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies Phase 1
Completed NCT05131490 - Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients N/A
Active, not recruiting NCT03899376 - A Trial Comparing Acute Toxicity in Patients With Gynecological Cancer Treated With VMAT N/A
Not yet recruiting NCT05407987 - Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) Phase 3
Recruiting NCT05891470 - To Explore the Benefits of the MonaLisa Touch® System in Gynaecological Cancer Patients Treated by (Chemo)-RT N/A
Not yet recruiting NCT05974995 - Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer N/A
Withdrawn NCT04368130 - SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care N/A